IBERSOL SGPS SA (IBS.LS) Stock Fundamental Analysis

ELI:IBS • PTIBS0AM0008

11.25 EUR
+0.1 (+0.9%)
Last: Feb 13, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to IBS. IBS was compared to 62 industry peers in the Hotels, Restaurants & Leisure industry. Both the profitability and the financial health of IBS get a neutral evaluation. Nothing too spectacular is happening here. While showing a medium growth rate, IBS is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • IBS had positive earnings in the past year.
  • In the past year IBS had a positive cash flow from operations.
  • IBS had positive earnings in 4 of the past 5 years.
  • In the past 5 years IBS always reported a positive cash flow from operatings.
IBS.LS Yearly Net Income VS EBIT VS OCF VS FCFIBS.LS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

1.2 Ratios

  • IBS has a Return On Assets of 1.91%. This is in the lower half of the industry: IBS underperforms 61.29% of its industry peers.
  • IBS has a Return On Equity (4.21%) which is comparable to the rest of the industry.
  • With a Return On Invested Capital value of 4.53%, IBS perfoms like the industry average, outperforming 41.94% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for IBS is significantly below the industry average of 12.12%.
  • The 3 year average ROIC (3.32%) for IBS is below the current ROIC(4.53%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 1.91%
ROE 4.21%
ROIC 4.53%
ROA(3y)9.49%
ROA(5y)5.17%
ROE(3y)16.68%
ROE(5y)5.68%
ROIC(3y)3.32%
ROIC(5y)N/A
IBS.LS Yearly ROA, ROE, ROICIBS.LS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40

1.3 Margins

  • IBS has a Profit Margin (2.56%) which is comparable to the rest of the industry.
  • IBS's Profit Margin has declined in the last couple of years.
  • The Operating Margin of IBS (5.83%) is comparable to the rest of the industry.
  • In the last couple of years the Operating Margin of IBS has declined.
  • IBS has a Gross Margin (52.62%) which is in line with its industry peers.
  • In the last couple of years the Gross Margin of IBS has remained more or less at the same level.
Industry RankSector Rank
OM 5.83%
PM (TTM) 2.56%
GM 52.62%
OM growth 3Y-40.02%
OM growth 5Y-6.76%
PM growth 3Y-42.54%
PM growth 5Y-4.22%
GM growth 3Y-0.29%
GM growth 5Y-0.28%
IBS.LS Yearly Profit, Operating, Gross MarginsIBS.LS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. Health

2.1 Basic Checks

  • IBS has a Return on Invested Capital (ROIC), which is below the Cost of Capital (WACC), which means it is destroying value.
  • The number of shares outstanding for IBS has been reduced compared to 1 year ago.
  • The number of shares outstanding for IBS has been increased compared to 5 years ago.
  • The debt/assets ratio for IBS is higher compared to a year ago.
IBS.LS Yearly Shares OutstandingIBS.LS Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
IBS.LS Yearly Total Debt VS Total AssetsIBS.LS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 2.17 indicates that IBS is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • IBS has a Altman-Z score (2.17) which is comparable to the rest of the industry.
  • The Debt to FCF ratio of IBS is 3.47, which is a good value as it means it would take IBS, 3.47 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 3.47, IBS is doing good in the industry, outperforming 70.97% of the companies in the same industry.
  • IBS has a Debt/Equity ratio of 0.66. This is a neutral value indicating IBS is somewhat dependend on debt financing.
  • IBS has a better Debt to Equity ratio (0.66) than 72.58% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 3.47
Altman-Z 2.17
ROIC/WACC0.72
WACC6.31%
IBS.LS Yearly LT Debt VS Equity VS FCFIBS.LS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M 300M 400M

2.3 Liquidity

  • A Current Ratio of 1.02 indicates that IBS should not have too much problems paying its short term obligations.
  • IBS's Current ratio of 1.02 is fine compared to the rest of the industry. IBS outperforms 64.52% of its industry peers.
  • IBS has a Quick Ratio of 1.02. This is a bad value and indicates that IBS is not financially healthy enough and could expect problems in meeting its short term obligations.
  • IBS has a better Quick ratio (0.92) than 61.29% of its industry peers.
Industry RankSector Rank
Current Ratio 1.02
Quick Ratio 0.92
IBS.LS Yearly Current Assets VS Current LiabilitesIBS.LS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. Growth

3.1 Past

  • IBS shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -16.66%.
  • IBS shows a decrease in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -8.23% yearly.
  • IBS shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 15.02%.
  • IBS shows a decrease in Revenue. Measured over the last years, the Revenue has been decreasing by -0.46% yearly.
EPS 1Y (TTM)-16.66%
EPS 3Y-29.2%
EPS 5Y-8.23%
EPS Q2Q%83.33%
Revenue 1Y (TTM)15.02%
Revenue growth 3Y32.48%
Revenue growth 5Y-0.46%
Sales Q2Q%7.53%

3.2 Future

  • IBS is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 17.57% yearly.
  • The Revenue is expected to grow by 7.42% on average over the next years.
EPS Next Y-38.06%
EPS Next 2Y-0.66%
EPS Next 3Y2.31%
EPS Next 5Y17.57%
Revenue Next Year15.95%
Revenue Next 2Y10.49%
Revenue Next 3Y8.64%
Revenue Next 5Y7.42%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
IBS.LS Yearly Revenue VS EstimatesIBS.LS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 200M 400M 600M
IBS.LS Yearly EPS VS EstimatesIBS.LS Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.5 -0.5 -1

More info and screens

Find the best growth stocksShow best growing peers

2

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 33.09, the valuation of IBS can be described as expensive.
  • IBS's Price/Earnings is on the same level as the industry average.
  • IBS's Price/Earnings ratio indicates a similar valuation than the S&P500 average which is at 27.97.
  • With a Price/Forward Earnings ratio of 35.55, IBS can be considered very expensive at the moment.
  • IBS's Price/Forward Earnings ratio is in line with the industry average.
  • The average S&P500 Price/Forward Earnings ratio is at 27.96. IBS is valued slightly more expensive when compared to this.
Industry RankSector Rank
PE 33.09
Fwd PE 35.55
IBS.LS Price Earnings VS Forward Price EarningsIBS.LS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • IBS's Price/Free Cash Flow ratio is rather cheap when compared to the industry. IBS is cheaper than 85.48% of the companies in the same industry.
Industry RankSector Rank
P/FCF 5.64
EV/EBITDA N/A
IBS.LS Per share dataIBS.LS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8 10

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-0.66%
EPS Next 3Y2.31%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

6

5. Dividend

5.1 Amount

  • With a Yearly Dividend Yield of 6.54%, IBS is a good candidate for dividend investing.
  • IBS's Dividend Yield is rather good when compared to the industry average which is at 1.32. IBS pays more dividend than 100.00% of the companies in the same industry.
  • IBS's Dividend Yield is rather good when compared to the S&P500 average which is at 1.79.
Industry RankSector Rank
Dividend Yield 6.54%

5.2 History

  • On average, the dividend of IBS grows each year by 48.65%, which is quite nice.
Dividend Growth(5Y)48.65%
Div Incr Years0
Div Non Decr Years0
IBS.LS Yearly Dividends per shareIBS.LS Yearly Dividends per shareYearly Dividends per share 2019 2022 2023 2024 2025 0.2 0.4 0.6 0.8 1

5.3 Sustainability

  • 213.50% of the earnings are spent on dividend by IBS. This is not a sustainable payout ratio.
  • The dividend of IBS is growing, but the earnings are growing slower. This means the dividend growth is not sustainable.
DP213.5%
EPS Next 2Y-0.66%
EPS Next 3Y2.31%
IBS.LS Yearly Income VS Free CF VS DividendIBS.LS Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M
IBS.LS Dividend Payout.IBS.LS Dividend Payout, showing the Payout Ratio.IBS.LS Dividend Payout.PayoutRetained Earnings

More info and screens

Find the best dividend stocksShow peers with best dividend

IBERSOL SGPS SA

ELI:IBS (2/13/2026, 7:00:00 PM)

11.25

+0.1 (+0.9%)

Chartmill FA Rating
GICS IndustryGroupConsumer Services
GICS IndustryHotels, Restaurants & Leisure
Earnings (Last)11-27
Earnings (Next)04-27
Inst Owners21.87%
Inst Owner ChangeN/A
Ins Owners0.03%
Ins Owner ChangeN/A
Market Cap466.99M
Revenue(TTM)522.73M
Net Income(TTM)13.37M
Analysts83.33
Price Target11.92 (5.96%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 6.54%
Yearly Dividend0.49
Dividend Growth(5Y)48.65%
DP213.5%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-2.11%
Min Revenue beat(2)-3.41%
Max Revenue beat(2)-0.81%
Revenue beat(4)2
Avg Revenue beat(4)4.87%
Min Revenue beat(4)-3.41%
Max Revenue beat(4)12.41%
Revenue beat(8)6
Avg Revenue beat(8)5.92%
Revenue beat(12)8
Avg Revenue beat(12)5.42%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-16.31%
EPS NY rev (3m)-25.78%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.48%
Valuation
Industry RankSector Rank
PE 33.09
Fwd PE 35.55
P/S 0.89
P/FCF 5.64
P/OCF 3.63
P/B 1.47
P/tB 2.13
EV/EBITDA N/A
EPS(TTM)0.34
EY3.02%
EPS(NY)0.32
Fwd EY2.81%
FCF(TTM)1.99
FCFY17.73%
OCF(TTM)3.1
OCFY27.55%
SpS12.59
BVpS7.64
TBVpS5.28
PEG (NY)N/A
PEG (5Y)N/A
Graham Number7.65
Profitability
Industry RankSector Rank
ROA 1.91%
ROE 4.21%
ROCE 5.74%
ROIC 4.53%
ROICexc 5.96%
ROICexgc 7.87%
OM 5.83%
PM (TTM) 2.56%
GM 52.62%
FCFM 15.84%
ROA(3y)9.49%
ROA(5y)5.17%
ROE(3y)16.68%
ROE(5y)5.68%
ROIC(3y)3.32%
ROIC(5y)N/A
ROICexc(3y)5.24%
ROICexc(5y)N/A
ROICexgc(3y)7.05%
ROICexgc(5y)N/A
ROCE(3y)4.21%
ROCE(5y)N/A
ROICexgc growth 3Y-24.94%
ROICexgc growth 5Y-3.32%
ROICexc growth 3Y-22.88%
ROICexc growth 5Y-3.24%
OM growth 3Y-40.02%
OM growth 5Y-6.76%
PM growth 3Y-42.54%
PM growth 5Y-4.22%
GM growth 3Y-0.29%
GM growth 5Y-0.28%
F-Score7
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.66
Debt/FCF 3.47
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 8.77%
Interest Coverage 250
Cash Conversion N/A
Profit Quality 619.36%
Current Ratio 1.02
Quick Ratio 0.92
Altman-Z 2.17
F-Score7
WACC6.31%
ROIC/WACC0.72
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)9.76%
Cap/Sales(5y)11.65%
Profit Quality(3y)200.89%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-16.66%
EPS 3Y-29.2%
EPS 5Y-8.23%
EPS Q2Q%83.33%
EPS Next Y-38.06%
EPS Next 2Y-0.66%
EPS Next 3Y2.31%
EPS Next 5Y17.57%
Revenue 1Y (TTM)15.02%
Revenue growth 3Y32.48%
Revenue growth 5Y-0.46%
Sales Q2Q%7.53%
Revenue Next Year15.95%
Revenue Next 2Y10.49%
Revenue Next 3Y8.64%
Revenue Next 5Y7.42%
EBIT growth 1Y34.45%
EBIT growth 3Y-20.54%
EBIT growth 5Y-7.19%
EBIT Next Year455.28%
EBIT Next 3Y83.41%
EBIT Next 5Y61.42%
FCF growth 1Y88.1%
FCF growth 3Y-0.14%
FCF growth 5Y-9.32%
OCF growth 1Y61.81%
OCF growth 3Y1.82%
OCF growth 5Y-6.35%

IBERSOL SGPS SA / IBS.LS FAQ

What is the ChartMill fundamental rating of IBERSOL SGPS SA (IBS.LS) stock?

ChartMill assigns a fundamental rating of 4 / 10 to IBS.LS.


Can you provide the valuation status for IBERSOL SGPS SA?

ChartMill assigns a valuation rating of 2 / 10 to IBERSOL SGPS SA (IBS.LS). This can be considered as Overvalued.


Can you provide the profitability details for IBERSOL SGPS SA?

IBERSOL SGPS SA (IBS.LS) has a profitability rating of 4 / 10.


What is the financial health of IBERSOL SGPS SA (IBS.LS) stock?

The financial health rating of IBERSOL SGPS SA (IBS.LS) is 5 / 10.


Can you provide the dividend sustainability for IBS stock?

The dividend rating of IBERSOL SGPS SA (IBS.LS) is 6 / 10 and the dividend payout ratio is 213.5%.